Geographic Variations in Diagnosis and Treatment of Ankylosing Spondylitis in the United States: A Real-World Study
ConclusionsAS diagnostic prevalence is increasing nationally, though it remains low among some states. bDMARD/tsDMARDs use was more common among patients treated by rheumatologists. Opioid and corticosteroid use is decreasing, though national rates remain high with significant state variability. Further education is needed, particularly in states with low prevalence and inadequate treatment, to improve diagnosis and treatment. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - December 19, 2021 Category: Rheumatology Source Type: research
Frequency and Duration of Early Non-serious Adverse Events in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with Tofacitinib
ConclusionsNon-serious AE incidence was generally similar in patients with RA or PsA receiving tofacitinib or placebo. Most events were mild or moderate and generally resolved within 4 weeks.Trial RegistrationClinicalTrials.gov identifiers: NCT00960440; NCT00847613; NCT00814307; NCT00856544; NCT00853385; NCT01877668; NCT01882439; NCT02187055. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - December 17, 2021 Category: Rheumatology Source Type: research
Post Hoc Analysis of the Correlation Between Patient-Reported Outcomes and Clinical Response to Repository Corticotropin Injection for Persistently Active Rheumatoid Arthritis
ConclusionsThese results confirm that clinical responses to RCI were directly correlated with patient perception of improvement. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - December 17, 2021 Category: Rheumatology Source Type: research
Association Between Janus Kinase Inhibitors Therapy and Mental Health Outcome in Rheumatoid Arthritis: A Systematic Review and Meta-analysis
ConclusionsJAK inhibitors results in clinically meaningful improvement in the mental health scores of the RA patients.PROSPERO Registration ID2021 CRD42021234466. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - December 13, 2021 Category: Rheumatology Source Type: research
Differential Changes in ACPA Fine Specificity and Gene Expression in a Randomized Trial of Abatacept and Adalimumab in Rheumatoid Arthritis
ConclusionsIn AMPLE, despite similar clinical outcomes, data showed that pharmacodynamic/genetic changes after 2 years of abatacept or adalimumab were consistent with drug MoAs. Further assessment of the relationship between such changes and clinical outcomes, including prediction of response, is warranted.Trial RegistrationClinicalTrials.gov identifier, NCT00929864. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - December 8, 2021 Category: Rheumatology Source Type: research
Reasons for Initiating Canakinumab among Patients with Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still ’s Disease in the U.S. Real-World Settings
ConclusionsIn US clinical practice, physician perceived/experienced efficacy/effectiveness of canakinumab and lack-of-response to previous treatment were the primary reasons for canakinumab initiation among patients with SJIA/AOSD. Physician perceived/experienced efficacy/effectiveness and convenient administration/dosing of canakinumab were the most common reasons for canakinumab initiation among children, whereas lack-of-response to previous treatment and ability to discontinue/spare steroids being the most frequent reasons among adults. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - December 7, 2021 Category: Rheumatology Source Type: research
Clinical Management of Herpes Zoster in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Receiving Tofacitinib Treatment
ConclusionAmong patients receiving tofacitinib, recurrent events were more common in patients with RA versus PsA; HZ duration was shorter for repeat events.Trial RegistrationNCT01262118, NCT01484561, NCT00147498, NCT00413660, NCT00550446, NCT00603512, NCT00687193, NCT01164579, NCT00976599, NCT01059864, NCT01359150, NCT02147587, NCT00960440, NCT00847613, NCT00814307, NCT00856544, NCT00853385, NCT01039688, NCT02187055, NCT00413699, NCT00661661, NCT01877668, NCT01882439, NCT01976364. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - December 6, 2021 Category: Rheumatology Source Type: research
Demographic and Clinical Characteristics of Patients with Sustained and Switching Treatments Using Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs: A Multicenter, Observational Cross-Sectional Study for Rheumatoid Arthritis
ConclusionsThe groups with sustained treatment and switching included patients with different disease activity status, although higher disease activity was determined in switchers. Overall, moderate disease activity and remission were the most common disease activity levels. Lower disease activity scores, lower hematologic manifestations, better functional status, and lesser radiographic damage are associated with sustain ed treatment. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - December 1, 2021 Category: Rheumatology Source Type: research
Treatment Patterns and Resource Utilization of Pregnant Women with Inflammatory Rheumatic Diseases or Psoriasis in Germany: A Claims Database Analysis
ConclusionsA reduction in pharmacological treatment during pregnancy was observed for women with IRD in Germany. Many women with IRD did not return to pre-pregnancy treatments after delivery, despite signs of disease exacerbation, such as hospitalization and initiation of treatment with corticosteroids/biologics, in this period. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - November 6, 2021 Category: Rheumatology Source Type: research
Knee Osteoarthritis Pain Management with an Innovative High and Low Molecular Weight Hyaluronic Acid Formulation (HA-HL): A Randomized Clinical Trial
ConclusionsA single intra-articular injection of an innovative high and low molecular weight hyaluronic acid formulation (HA-HL) is effective in providing fast, sustained, and clinically relevant reductions in pain, functional limitation, and health-related quality of life that were apparent at 1 week after the intra-articular injection and maintained throughout the 24-week follow-up in subjects with painful knee osteoarthritis, with a good safety profile.Trial RegistrationClinicalTrials.gov identifier: NCT03200288. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - November 6, 2021 Category: Rheumatology Source Type: research
Abatacept is Efficacious in the Treatment of Older Patients with csDMARD-Refractory Rheumatoid Arthritis: A Prospective, Multicenter, Observational Study
ConclusionsThis prospective study demonstrated that abatacept is efficacious and safe in older patients with RA and a history of being refractory to csDMARDs. Abatacept was shown to be more efficacious than adding or switching to a new csDMARD in both younger and older csDMARD-refractory patients with RA.Trial RegistrationUMIN000014913. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - November 6, 2021 Category: Rheumatology Source Type: research
Systematic Review and Meta-Analysis of Inflammatory Bowel Disease Adverse Events with Anti-Interleukin 17A Agents and Tumor Necrosis Factor Inhibitors in Rheumatic Disease and Skin Psoriasis
ConclusionsIBD events were rare, occurring at rates similar to biologic-naive groups. We could not find statistically significant differences in risk of new or recurrent IBD between treatment and control groups using selected meta-analytical methods for low event rate scenarios. Meta-analyses of this topic require more IBD events, ideally without pooling heterogeneous groups. Larger, thoroughly reported trials with systematic and detailed safety reporting are required to improve risk estimation and to make accurate inferences. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - November 6, 2021 Category: Rheumatology Source Type: research
Correction to: Repository Corticotropin Injection for Persistently Active Systemic Lupus Erythematosus: Results from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
(Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - November 6, 2021 Category: Rheumatology Source Type: research
The Economic Burden of Lupus Nephritis: A Systematic Literature Review
ConclusionsThe consensus across the 22 studies was that the economic burden of LN is substantial, particularly in active or severe disease, or if there is progression to ESKD. Total direct cost may be underestimated in claims data given the challenges of identifying patients with LN. Further studies are vital to ascertain the cost of renal flares; a renal flare is likely to result in a period of increased HCRU, which could be mitigated by treatments that extend renal remission. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - November 3, 2021 Category: Rheumatology Source Type: research
Correction to: Identification of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis Using Machine Learning and Clinical Trial Data
(Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - October 29, 2021 Category: Rheumatology Source Type: research
